2019 Scripps MD Anderson's Oncology Update

 

2019 Scripps MD Anderson's Oncology Update
Avatar

CLL Practice Changing Studies From ASCO 2019: Acalabrutinib + Obinutuzumab in R/R, Superiority of Venetoclax/obinutuzumab in Elderly Patients & Comparing Frontline Options

By 2019 Scripps MD Anderson's Oncology Update FEATURING Alan Saven
By 2019 Scripps MD Anderson's Oncology Update FEATURING Alan Saven
510 views
August 19, 2019
0 Comments
Login to view comments. Click here to Login
Hematologic Oncology
16:21
2019 Scripps MD Anderson's Oncology Update

CLL Practice Changing Studies From ASCO 2019: Acalabrutinib + Obinut…

Feat. A. Saven
22:43
2019 Scripps MD Anderson's Oncology Update

Myeloma Practice Changing Studies From ASCO 2019: High-Risk Smolderi…

Feat. A. Saven
12:47
2019 Scripps MD Anderson's Oncology Update

Lymphoma Practicing Changing ASCO19 Studies: Novel Agents Prior to R…

Feat. A. Saven